To schedule a new patient appointment call 844-CANCERNJ (844-226-2376)
To schedule a follow-up appointment call 732-235-7615
For all other inquiries call 732-235-2465.
Sanjay Goel, MD, M.S. is an attending physician and a Professor of Medicine at Rutgers Cancer Institute of New Jersey. He received his medical degree from Christian Medical College, Vellore, India, and then did a residency in internal medicine and fellowship in Hematology and Medical Oncology. He also completed a 2-year program obtaining a Master of Science (M.S.) degree in Clinical Research from the Albert Einstein College of Medicine.
Dr. Goel is the Director of Phase I Therapeutics at Rutgers Cancer Institute. He has an interest in drug development of anti-cancer agents, and development of biomarkers of drug response. He has extensive experience in cancer clinical trials, in phase I, and in phase II and III trials in gastrointestinal and genitourinary malignancies. His clinical interests lie in immunotherapy of cancer in general and colorectal cancer in particular. He runs a research laboratory with a focus on drug and biomarker development for patients with colorectal cancer. His work also includes outcomes of health in minority patients and health disparities.
He has multiple research awards to his credit and has over 100 research publications. He has been the recipient of the Advanced Clinical Research Award (ACRA) in colorectal cancer by the Conquer Cancer Foundation (CCF), of the American Society of Clinical Oncology (ASCO), and has also funded by the National Institutes of Health. He has served on the CCF Grant Review Committee, and as the track leader of the Scientific Program Committee in the “Developmental Therapeutics and Translational Research – Immunotherapy” track, of ASCO.
Medical Oncology, Clinical trials, Gastrointestinal cancers
Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with your insurance company they are still a participating plan prior to receiving services or care. Each plan is different and some provide different levels of coverage that could make a difference in your out-of-pocket costs. It is always best for the patient receiving care to contact their insurance company to obtain more information.
Dr. Sanjay Goel discusses clinical trials and the South Asian community with EBC radio. Listen here
Minority Representation in Clinical Trials is Critical
According to the most recent drug trial data from the FDA, only 11 percent of the near 5,000 participants in the clinical trials of 18 new cancer drugs approved in 2020 were Black or Hispanic, highlighting the low minority representation in clinical trials, even though these groups are more likely to be affected by certain cancers. Learn more
Dr. Goel on the Need for Diverse Representation in Clinical Trials
Sanjay Goel, MD, MS, discusses the need for diverse representation in clinical trials with OncLive. Listen here